Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00 2022-09-26 pm EDT
42.70 USD   -1.86%
09/26Insider Sell: Intra-Cellular Therapies
MT
08/22Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Advance Auto Parts...
MS
08/22Goldman Sachs Cuts Intra-Cellular Therapies to Neutral From Buy, Price Target to $49 From $64
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2022

08/09/2022 | 08:30am EDT
Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' second quarter earnings call. [Operator Instructions] As a reminder, today's conference call is being recorded. I would...


© S&P Capital IQ 2022
All news about INTRA-CELLULAR THERAPIES, INC.
09/26Insider Sell: Intra-Cellular Therapies
MT
08/22Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Ad..
MS
08/22Goldman Sachs Cuts Intra-Cellular Therapies to Neutral From Buy, Price Target to $49 Fr..
MT
08/15Insider Sell: Intra-Cellular Therapies
MT
08/11Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps..
MT
08/10Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Ratin..
MT
08/10Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains ..
MT
08/09Intra Cellular Therapies : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORP..
PU
08/09Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2..
CI
08/09Intra-Cellular Therapies Q2 Net Loss Widens, Revenue Climbs
MT
More news
Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.
More recommendations
Financials (USD)
Sales 2022 235 M - -
Net income 2022 -305 M - -
Net cash 2022 285 M - -
P/E ratio 2022 -13,1x
Yield 2022 -
Capitalization 4 031 M 4 031 M -
EV / Sales 2022 15,9x
EV / Sales 2023 8,94x
Nbr of Employees 512
Free-Float 97,5%
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 42,70 $
Average target price 69,15 $
Spread / Average Target 62,0%
EPS Revisions
Managers and Directors
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Suresh Durgam Chief Medical Officer & Senior Vice President
Karen Patruno Sheehy Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
INTRA-CELLULAR THERAPIES, INC.-18.42%4 031
GILEAD SCIENCES, INC.-14.14%78 135
REGENERON PHARMACEUTICALS, INC.8.64%73 350
VERTEX PHARMACEUTICALS26.04%70 983
BIONTECH SE-50.48%31 021
WUXI APPTEC CO., LTD.-40.57%28 544